中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D
Innovation
Product Pipeline
Achievements
Products
Drug Products
Biological products
APIs
Intermediates
Boranes
OLED Materials
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2025
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
7,8,9,10-Tetrahydro-8-(trifluoroacetyl)-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane
3-Fluoro-5-hydroxybenzonitrile
[1,2,4]Triazolo[1,5-a]pyridin-7-ol
1H-Indazole-7-carboxylic Acid
N-Tert-butyl-1H-indazole-7-carboxamide
Dimorpholinophosphinyl Chloride
Fmoc-L-glutamicacidgamma-methylester
2-(2-Amino-5-bromobenzoyl)pyridine
4-Methylidenepiperidine, Hydrochloride
1-(((2R,3S)-2-(2,4-Difluorophenyl)-3-methyloxiran-2-yl)methyl)-1H-1,2,4-triazole
(2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol
(R)-2-((4-Nitrophenethyl)amino)-1-phenylethanol Hydrochloride
(R)-(+)-1-(1-Naphthyl)ethylamine
N-((R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)-propanamide
(R)-(+)-1-Phenylethanol
(S)-(-)-1-Phenylethanol
Pyridine-2-sulfonyl fluoride
Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection
Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA
Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA
Viwit's Nitroglycerin Sublingual Tablets Approved by FDA
Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"
Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.
Product Name:
CAS#:
Search
中文
EN
